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l Introduction
Ritodrine hydrochloride is a beta-sympathomime-
tic drug, with predominantly beta 2-effects, which
is effective in the treatment of premature labor
[6]. The compound may be administered intra-
venously, intramusculary or orally. It is inactivated
by glucuronide and sulphate conjugation and
excreted in the urine.
The placental transfer of ritodrine was initially
suspected on clinical grounds, namely the increase
in fetal heart rate associated with ritodrine infu-
sion [1]. Using radioactively labelled drug, KLEIN -
HOUT and VETH [5] demonstrated placental
transfer in the sheep. In this model, fetal blood
levels of radioactivity never exceeded 20% of
those present in the ewe. These results are in
accordance with similar investigations undertaken
by COSMI [2]. However, data from studies using
radiolabelled drug give no indication of the ratio
between unaltered ritodrine and its conjugates.
WEIDINGER [8] and WIEST [9] published results
of diaplacental passage, using tritium-tagged feno-
terol in legal abortions.
The development of radioimmunoassay for rito-
drine [3, 7] permitted measurement of active drug
without the inactive conjugates. In a study using
the radioimmunoassay technique in pregnant
women, GANDAR et al. [3] confirmed the placen-
tal transfer of ritodrine itself in humans.
The present study reports data on ritodrine con-
centrations in maternal and fetal serum and amnio-
tic fluid, measured by radio-immunoassay. Sam-
ples were taken from eight patients undergoing
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elective cesarian section following intravenous
infusion of ritodrine.
2 Materials and methods
2. l Radioimmunoassay of ritodrine
Unlabelled ritodrine hydrochloride of pharma-
ceutical grade, tritiumlabelled ritodrine hydro-
chloride and anti-ritodrine serum were supplied by
DUPHAR B. V., Weesp, The Netherlands.
0300-5577/82/0010-0119S02.00
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The anti-ritodrine antiserum was tested for im-
munological cross reactions with: Isoxsuprine,
fenoterol, salbutamol, terbutaline, hLH, hFSH,
hCG, hCGa, hCG/3 and relaxin. The only cross-
reaction was with fenoterol, but even this was
slight and not significant. Progesterone, 17/J-estra-
diol, adrenalin, noradrenalin, albumin and prosta-
glandins E2 and F2a showed no interference with
the assay procedure, details of which are pubÜshed
elsewhere [7].
2.2 Volunteers
Eight healthy, pregnant, women between 37 and
41 weeks of gestation and not in labor, who were
to undergo elective cesarian section, agreed to
participate after being fully informed on the aim
of the study and the possible effects of ritodrine
infusion. The indications for cesarian section were:
Iterative (n = 4), pathological pelvis (n = 3) and a
breech presentation (n = 1). The clinical, hormonal
and echographical investigations gave no abnormal
results or contra-indication to the administration
ofbeta-mimetics.
2.3 Procedure
The patients were placed in the left lateral position
and ritodrine infusion was started (Fig. 1). The in-
fusion was controlled by means of a drop-by-drop
regulation pump. The dose was 2 g · kg"1 · min"1
for the first 30 minutes, to assess maternal cardio-
Väscular adaptation, and then 4 /ig · kg^1 - min"1
for 90 minutes (Total dose 420 % - kg"1). Every
30 minutes maternal heart rate and blood pressure
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Fig. 1. Schedule of biological fluid sampling. MB = maternal peripheral blood sampling CS - time of cesarian section
and utenne vem, umbilical artery and vein blood sampling, and amniotic fluid sampling.
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peripheral vein for ritodrine assay. Surgical proce-
dures started with patients in the half left lateral
decubitus position. After anesthesia was estab-
lished, the following procedures were carried out
in rapid succession: ritodrine infusion stopped,
peripheral blood sampling, laparotomy, uterine
vein blood sampling, amniotic fluid sampling by
amniocentesis, hysterotomy, fetal extraction, um-
bilical artery and vein blood sampling, child placed
under pediatric care. All cesarian sections were
performed by the same operator. One and four
hours after anesthesia was established, maternal
blood samples were drawn for ritodrine assay.
3 Results
3.1 Newborns
Tab. I shows the data for the newborn babies. All
the children's weights feil within the 10° to 90°
percentiles for gestational age. One baby had a one
minute APGAR score less than 7 and another
acidosis (pH < 7.15) related to maternal "hypoxic-
hypercapnic" Status during tracheal intubation.
The course during the neonatal period was normal
for all babies.
3.2 Ritodrine concentrations
Fig. 2 shows the development of the maternal
ritodrine levels during the infusion and after its
discontinuation. Tab. II shows simultaneous
ritodrine concentrations in the maternal compart-
ment (peripheral and uterine veins) and the fetal
compartment (umbilical artery and vein, amniotic
fluid) at the moment of cesarian section, i.e., after
2 hours infusion.


























































































Our results, with respect to peripheral maternal
blood, appear to agree with those of other authors.
GANDAR et al. [3] infused six non-pregnant wo-
men with 150 Mg · min"1 for 60 minutes and ob-
tained serum ritodrine concentrations of 28.9 ±
2.5 ng/ml (mean ± SEM) at 20 minutes and 41.0 ±
l .9 ng/ml at 50 minutes.
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Fig. 2. Ritodrine concentrations (ng/ml) in maternal serum during and after ritodrine infusion.
Comparison of concentrations, after 2 hours in-
fusion, between the peripheral venous blood and
uterine venous blood, showed a significant differ-
ence (p < 0.02, paired-t test). The mean con-
centrations were, respectively 54.2 ±11.8 ng/ml
and 37.5 ± 10.3 ng/ml. This difference probably
reflects the trans-placental passage.
In the fetal circulation, ritodrine levels in blood
from the umbilical vein and artery did not differ
significantly. The respective mean concentrations
were 16.6 ± 8.9 ng/ml and 15.8 ± 4.8 ng/ml.
The mean ratio of fetal vein and peripheral mater-
nal vein serum ritodrine concentrations was 0.30 ±
0.13 (mean ± SD). This is at variance with the
results from GANPAR et al. [3] who found a mean
ratio of 0.64 ± 0.25 (mean ± SD). However, com-
parison of results is hampered by the lack of
standardization in the latter study. INGEMARS-
SON et al. [4] studied the concentrations of
terbutaline in plasma after bolüs intravenous
administration of 250 g during the second stage
of labor. The found of mean ratio for mixed cord
blood: Maternal vein blood of 0.36 ±0.15 (mean
± SD). Finally, the similarity between mean con-
centrations in amniotic fluid (15.2 ± 8.7 ng/ml)3
umbilical arterial blood (15.8 ± 4.8 ng/ml) and
umbilical venous blood (16.6 ± 8.9 ng/ml) is
striking. In äs far äs the ritodrine in the amniotic
fluid originales in the fetal urine, these results
suggest that the fetus does not conjugate this drug.
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Summary
Ritodrine hydrochloride concentrations were measured
by radioimmunoassay in maternal and fetal sera and
amniotic fluid from eight, pregnant, volunteers.
Each patient agreed to have 420 Mg · kg"1 of ritodrine
infused intra-venously over two hours prior to elective
cesarian section. During infusion a blood sample was
taken every 30 minutes from a maternal peripheral vein.
Once anasthesia was established the infusion was dis-
continued. During surgery, samples were drawn from
maternal peripheral vein, uterine vein, umbilical artery
and vein, and amniotic fluid. All the children delivered
were healthy and had a normal course during the neo-
natal period.
Ritodrine concentrations in maternal and fetal compart-
ments at the time of cesarian section were 54.2 ±
11.8 ng/ml (mean ± S.D.) in maternal peripheral vein,
37.5 ± 10.3 ng/ml in uterine vein, 15.8 ± 4.8 ng/ml in
umbilical artery, 16.6 ± 8.9 ng/ml in umbilical vein, and
15.2 ± 8.7 ng/ml in amniotic fluid. There was a statisti-
cally significant difference (p < 0.02, paired-t test) be-
tween the mean ritodrine concentrations in sera from the
maternal peripheral vein and uterine vein. This difference
probably reflects transplacental passsage. The mean ratio
of fetal vein and peripheral maternal vein serum ritodrine
concentrations was 0.30 ± 0.13 (mean ± SD).
The similarity between mean ritodrine concentrations in
amniotic fluid, and sera from umbilical arterial and
venous blood was striking. These results suggest that the
fetus does not conjugate the drug.
Keywords: Amniotic fluid, betamimetic drug, fetus, placental transfer, radioimmunoassay, ritodrine hydrochloride.
Zusammenfassung
Ritodrine-Werte im mütterlichen und fetalem Serum und
im Fruchtwasser
Durch ein radioimmunologisches Verfahren wurde der
Ritodrinegehalt bei der Mutter und auch beim Feten be-
stimmt.
Acht freiwilligen Patientinnen wurde vor geplanter, ter-
mingerechter Sectio eine zwei Stunden dauernde Infusion
420 Mg · kg'1 Ritodrine verabreicht.
Nach allmählichem Anstieg der mütterlichen Blutkonzen-
tration von Ritodrine während der Infusion ergaben sich
zum Zeitpunkt der Sectio folgende Werte: Im peripheren
Venenblut der Mutter 54,2 ± 11,8 ng/ml; im Plexus
venosus uteri 37,5 ± 10,3 ng/ml; für den Nabelstrang
15,8 ± 4,8 ng/ml im arteriellen und 16,6 ± 8,9 ng/ml in
venösen Blut, sowie 15,2 ± 8,7 ng/ml im Fruchtwasser.
Diese Ergebnisse lassen auf einen statistisch signifikanten
Konzentrationsunterschied zwischen dem mütterlichen
Blutkreislauf und Plexus venosus uteri (p < 0.02) schlie-
ßen. Dieser Unterschied spiegelt sehr wahrscheinlich den
transplazentaren Übergang des Ritodrine wider.
Das Verhältnis der Durchschnittswerte in Nabelstrang-
vene und mütterlichem Blut beträgt 0,30 ± 0.13.
Schließlich wurde Ritodrine auch im Fruchtwasser nach-
gewiesen. Hier entspricht der Mittelwert dem des fetalen
Blutes, was vermuten läßt, daß der Fetus die Substanz
nicht abbaut.
Schlüsselwörter: Betamimetika, Fetus, Fruchtwasser, Radioimmunoassay, Ritodrine hydrochloride, transplazentarer
Übergang.
Resume
Concentrations de ritodrine dans le serum foetal et
maternel et dans le liquide amniotique
Les concentrations de ritodrine ont ete mesurees par
technique radioimmunologique dans le serum maternel et
dans le liquide amniotique chez 8 volontaires enceintes.
Chaque patiente a regu 420 Mg · kg'1 de ritodrine en
perfusion I.V. pendant 2 heures avant une cesarienne
elective. Au cours de la perfusion, un pretövement sanguin
a ete pratique toutes les 30 minutes. A l'induction de k
narcose, la perfusion ä stoppee et au cours de
l'intervention, les prelevements suivants ont ete realises
pour dosage de ritodrine: veine peripherique maternelle,
veine uterine, artere ombilicale, veine ombiUcaJe, liquide
amniotique. Tous les enfants sont nes dans de bonnes
conditions cliniques et biochimiques et ont presente une
evolution neonatale normale.
Les concentration de ritodrine dans les compartiments
maternel et foetal au moment de la cesarienne etaient les
suivantes: 54,2 ± 11,8 ng/ml (moyenne ± D.S.) dans la
veine peripherique maternelle, 37,5 ± 10,3 ng/ml dans la
veine uterine, 15,8 ± 4,8 ng/ml dans Tattere ombilicale,
16,6 ± 8,9 ng/ml dans k veine ombilicale, et 15,2 ±
8,7 ng/ml dans le liquide amniotique.
H existe une difference statistiquement significative
(p < 0,02) entre la concentration moyenne de ritodrine
dans la veine peripherique et dans la veine uterine. Cette
difference reflete probablement le passage trans-
placentaire. Le rapport moyen veine ombilicale/veine
peripherique maternelle dans la concentration de ritodrine
est de 0,30 ± 0,13 (moyenne ± D.S.).
La süniütude entre les concentrations de ritodrine dans le
liquide amniotique, Tariere ombilicale et la veine
ombilicale est etonnante. Ces resultats suggerent que le
foetus ne conjugue pas la substance.
Mots-cles: Beta-mimetique, foetus, liquide amniotique, radioimmunoassay, ritodrine hydrochloride, transfert
placentaire.
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